CR20200416A - Nuevos compuestos heterocíclicos - Google Patents

Nuevos compuestos heterocíclicos

Info

Publication number
CR20200416A
CR20200416A CR20200416A CR20200416A CR20200416A CR 20200416 A CR20200416 A CR 20200416A CR 20200416 A CR20200416 A CR 20200416A CR 20200416 A CR20200416 A CR 20200416A CR 20200416 A CR20200416 A CR 20200416A
Authority
CR
Costa Rica
Prior art keywords
magl
oxazine
inhibitors
monoacylglycerol lipase
sup
Prior art date
Application number
CR20200416A
Other languages
English (en)
Inventor
Luca Gobbi
Martin Ritter
Joerg Benz
Bernd Kuhn
Rui Chen
Satoshi Tsuchiya
Charles Bell
Benoit Hornsperger
Zbinden Katrin Groebke
Carsten Kroll
Hans Richter
Uwe Grether
Dennis Jul Hansen
Buelent Kocer
Fionn O`Hara
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20200416A publication Critical patent/CR20200416A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

<p>La invención proporciona nuevos compuestos heterocíclicos que presentan la fórmula general (Ic), en la que A, L, X, m, n y R<sup>20</sup> a R<sup>23</sup> son tal como se describe en la presente memoria, composiciones que incluyen los compuestos, procedimientos de preparación de los compuestos y métodos de utilización de los compuestos. </p>
CR20200416A 2018-03-22 2019-03-22 Nuevos compuestos heterocíclicos CR20200416A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18163273 2018-03-22
CN2019075372 2019-02-18
PCT/EP2019/057174 WO2019180185A1 (en) 2018-03-22 2019-03-22 Oxazine monoacylglycerol lipase (magl) inhibitors

Publications (1)

Publication Number Publication Date
CR20200416A true CR20200416A (es) 2020-10-26

Family

ID=65818027

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20200416A CR20200416A (es) 2018-03-22 2019-03-22 Nuevos compuestos heterocíclicos

Country Status (27)

Country Link
US (2) US20210107920A1 (es)
EP (1) EP3768684B1 (es)
JP (1) JP7308220B2 (es)
KR (1) KR20200136425A (es)
CN (1) CN111936503B (es)
AU (1) AU2019238381B2 (es)
BR (1) BR112020014992A2 (es)
CA (1) CA3089443A1 (es)
CL (1) CL2020002423A1 (es)
CO (1) CO2020009567A2 (es)
CR (1) CR20200416A (es)
DK (1) DK3768684T3 (es)
ES (1) ES2942319T3 (es)
FI (1) FI3768684T3 (es)
HR (1) HRP20230388T1 (es)
HU (1) HUE061584T2 (es)
IL (1) IL276031B2 (es)
LT (1) LT3768684T (es)
MX (1) MX2020008894A (es)
PE (1) PE20201185A1 (es)
PH (1) PH12020500661A1 (es)
PL (1) PL3768684T3 (es)
RS (1) RS64156B1 (es)
SG (1) SG11202007608UA (es)
SI (1) SI3768684T1 (es)
TW (1) TWI818967B (es)
WO (1) WO2019180185A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR114136A1 (es) 2017-10-10 2020-07-29 Hoffmann La Roche Compuestos heterocíclicos
CN111386269A (zh) 2017-11-28 2020-07-07 豪夫迈·罗氏有限公司 新型杂环化合物
WO2019134985A1 (en) 2018-01-08 2019-07-11 F. Hoffmann-La Roche Ag Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors
MA53219A (fr) 2018-08-13 2021-11-17 Hoffmann La Roche Nouveaux composés hétérocycliques en tant qu'inhibiteurs de monoacylglycérol lipase
US20210094971A1 (en) * 2019-09-09 2021-04-01 Hoffmann-La Roche Inc. Heterocyclic compounds
MX2022002311A (es) * 2019-09-12 2022-03-25 Hoffmann La Roche Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de monoacilglicerol lipasa (magl).
AU2020355507A1 (en) * 2019-09-23 2022-02-17 F. Hoffmann-La Roche Ag Heterocyclic compounds
WO2021058444A1 (en) * 2019-09-24 2021-04-01 F. Hoffmann-La Roche Ag Heterocyclic compounds
JP2022549306A (ja) * 2019-09-24 2022-11-24 エフ．ホフマン－ラ ロシュ アーゲー モノアシルグリセロールリパーゼ（ｍａｇｌ）の蛍光プローブ
MX2022002711A (es) * 2019-09-24 2022-03-22 Hoffmann La Roche Nuevos inhibidores heterociclicos de monoacilglicerol lipasa (magl).
CN115989228A (zh) 2020-09-03 2023-04-18 豪夫迈·罗氏有限公司 杂环化合物
WO2023060362A1 (en) * 2021-10-15 2023-04-20 Genetolead Inc. Ras inhibitors, compositions and methods of use thereof
WO2023247670A1 (en) * 2022-06-24 2023-12-28 F. Hoffmann-La Roche Ag New heterocyclic-carbonyl-cyclic compounds as magl inhibitors
WO2024061853A1 (en) * 2022-09-20 2024-03-28 F. Hoffmann-La Roche Ag Fluorescent probes for magl

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7579495B2 (en) 2003-12-19 2009-08-25 Momentive Performance Materials Inc. Active-releasing cyclic siloxanes
ES2337728T3 (es) 2005-06-20 2010-04-28 Schering Corporation Piperidinas sustituidas unidas a carbono y sus derivados utiles como antagonistas de histamina h3.
CA2637531A1 (en) 2006-02-17 2007-08-30 Memory Pharmaceuticals Corporation Compounds having 5-ht6 receptor affinity
US7872028B2 (en) 2006-04-05 2011-01-18 Vitae Pharmaceuticals, Inc. Diaminopropanol renin inhibitors
WO2011059118A1 (ko) 2009-11-10 2011-05-19 Kim Hyun Jeen 후각인지능력 검사 시스템
WO2012155199A1 (en) 2011-05-16 2012-11-22 Bionomics Limited Amine derivatives as potassium channel blockers
CN107982266B (zh) 2012-01-06 2021-07-30 H.隆德贝克有限公司 氨基甲酸酯化合物及其制备和使用方法
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
WO2016109501A1 (en) 2014-12-30 2016-07-07 Karos Pharmaceuticals, Inc. Amide compounds as tryptophan hydroxylase inhibitors
US20180148429A1 (en) 2015-05-13 2018-05-31 Selvita S.A. Substituted quinoxaline derivatives
EP3298003B1 (en) 2015-05-21 2023-04-19 GlaxoSmithKline Intellectual Property Development Limited Benzoimidazole derivatives as pad4 inhibitors
EP3310773B1 (en) 2015-06-18 2020-12-02 89Bio Ltd. Substituted 4-benzyl and 4-benzoyl piperidine derivatives
CN105198903B (zh) * 2015-11-09 2016-08-24 代先慧 一种治疗急性上呼吸道感染的药物组合物
EP3438109B1 (en) 2016-03-31 2021-08-25 Takeda Pharmaceutical Company Limited Heterocyclic compound

Also Published As

Publication number Publication date
TWI818967B (zh) 2023-10-21
RU2020133991A (ru) 2022-04-22
JP7308220B2 (ja) 2023-07-13
CA3089443A1 (en) 2019-09-26
ES2942319T3 (es) 2023-05-31
HUE061584T2 (hu) 2023-07-28
CN111936503B (zh) 2023-09-12
PE20201185A1 (es) 2020-11-03
MX2020008894A (es) 2020-10-12
AU2019238381A1 (en) 2020-08-06
EP3768684A1 (en) 2021-01-27
CO2020009567A2 (es) 2020-08-10
WO2019180185A8 (en) 2020-10-22
DK3768684T3 (da) 2023-04-24
LT3768684T (lt) 2023-04-25
BR112020014992A2 (pt) 2020-12-29
HRP20230388T1 (hr) 2023-06-23
FI3768684T3 (fi) 2023-04-26
US20210107920A1 (en) 2021-04-15
AU2019238381B2 (en) 2022-07-07
SG11202007608UA (en) 2020-09-29
SI3768684T1 (sl) 2023-06-30
PL3768684T3 (pl) 2023-07-10
WO2019180185A1 (en) 2019-09-26
TW202003525A (zh) 2020-01-16
US20230117324A1 (en) 2023-04-20
JP2021517575A (ja) 2021-07-26
IL276031A (en) 2020-08-31
EP3768684B1 (en) 2023-02-22
CN111936503A (zh) 2020-11-13
RS64156B1 (sr) 2023-05-31
PH12020500661A1 (en) 2021-06-28
IL276031B2 (en) 2023-06-01
KR20200136425A (ko) 2020-12-07
CL2020002423A1 (es) 2021-02-19

Similar Documents

Publication Publication Date Title
CR20200416A (es) Nuevos compuestos heterocíclicos
MX2021001433A (es) Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa.
CR20210056A (es) Nuevos compuestos heterocíclicos como inhibidores de monoacilglicerol lipasa
MX2021005714A (es) Nuevos compuestos heterociclicos.
CR20220118A (es) Nuevos inhibidores heterocíclicos de monoacilglicerol lipasa (magl)
MX2022002311A (es) Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de monoacilglicerol lipasa (magl).
MX2021000795A (es) Compuestos heterociclicos para inhibir la actividad de shp2.
MX2022002554A (es) Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de monoacilglicerol lipasa (magl).
CR20220116A (es) Compuestos heterocíclicos
PH12019500664A1 (en) New isoxazolyl ether derivatives as gaba a alpha5 pam
MX2013006101A (es) Compuestos heterociclicos nitrogenados sustituidos fusionados en posicion 6,6 y usos de los mismos.
MX2015010775A (es) Benzoxazoles sustituidos y metodos para usarlos.
MX2020009234A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.
CR20220004A (es) Nuevos compuestos heterocíclicos
CR20220117A (es) Compuestos heterocíclicos
MX2023002224A (es) Compuestos heterociclicos.
MX2023012477A (es) Compuestos heterociclicos.
MX2020013518A (es) Nuevos derivados de isoxazolil eter como moduladores alostericos positivos (pam) del receptor de acido gamma-aminobutirico a alfa5 (gaba a alfa5).
MX2021002087A (es) Derivados de heteroarilo biciclicos.